NEW YORK, March 10 (GenomeWeb News) - Investment bank Caris & Company downgraded Orchid Cellmark stock to "average" from "above average" yesterday after the company cut its 2005 revenue projections.


To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.